RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. SPY
4. MU
5. META
6. FDX
7. IBM
8. PRIM
9. ACN
10. USO

Go back to RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis
AbbVie (NYSE: ABBV) Delayed: 234.76 +4.75 (2.07%)
Previous Close $230.01    52 Week High $68.12 
Open $232.97    52 Week Low $50.71 
Day High $235.31    P/E 50.92 
Day Low $231.30    EPS $4.61 
Volume 7,182,891